Want to see ARMP full AI Analyst Report?
ARMP Stock Chart & Stats
$11.50
$0.11(5.39%)
At close: 4:00 PM EST
$11.50
$0.11(5.39%)
Day’s Range― - ―
52-Week Range$1.81 - $16.34
Previous CloseN/A
Volume48.90K
Average Volume (3M)67.60K
Market Cap
$216.23M
Enterprise Value$628.10M
Total Cash (Recent Filing)$4.75M
Total Debt (Recent Filing)$373.67M
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 18, 2026EPS Estimate
-0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.77
Shares Outstanding36,710,810
10 Day Avg. Volume60,834
30 Day Avg. Volume67,596
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market Cap2.90
Enterprise Value/Revenue212.34
Enterprise Value/Gross Profit294.19
Enterprise Value/Ebitda-2.39
Forecast
1Y Price Target
$17.50Price Target Upside52.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-2.9
Revenue Forecast (FY)$1.80M
Bulls Say, Bears Say
Bulls Say
Non-dilutive DoD FundingAdditional non-dilutive DoD capital materially lowers near-term funding pressure and reduces immediate dilution risk while underwriting Phase 3 preparations. Government backing also validates program relevance in antimicrobial resistance and supports longer-range development timelines and credibility with partners.
Regulatory Designations (Fast Track, QIDP)Fast Track and QIDP grant more FDA interaction, rolling review, and potential accelerated pathways, structurally shortening regulatory timelines if trials succeed. These designations strengthen the program's regulatory pathway, potentially improving approval probability and preserving exclusivity economics long-term.
Board Commercial Expertise AddedAdding a seasoned commercial leader with first-in-class anti-infective launch experience improves commercialization planning, payer access strategy, and launch readiness. This durable capability increases the odds of an effective market entry if AP-SA02 is approved, enhancing long-term competitive positioning.
Bears Say
Negative Stockholders' EquitySustained negative equity materially limits financial flexibility, distorts leverage metrics, and heightens refinancing and dilution risk. For a clinical-stage biotech facing costly late-stage trials, negative equity increases the likelihood of dilutive financing or restrictive covenants, constraining strategic optionality.
High Cash Burn, Limited Cash RunwayPersistent negative operating and free cash flows combined with low reported cash create acute funding risk that can delay trials or force unfavorable financings. Reliance on external capital or secured loans to sustain operations undermines operational independence and can compress timelines for development milestones.
Very Large Losses, Small/choppy RevenueExtremely large net losses relative to minimal revenue indicate the business is not self-funding and remains R&D-dependent. Continued negative profitability increases pressure for partner deals or dilutive financings, reducing runway for pipeline programs and weakening long-term sustainability if milestones slip.
Armata Pharmaceuticals News
ARMP FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was $1.81 and its highest was $16.34 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is $216.23M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is Aug 18, 2026 which is in 46 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on May 13, 2026. The company reported -$3.16 earnings per share for the quarter, missing the consensus estimate of -$0.38 by -$2.78.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.45.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,710,810 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -$3.16 in its last earnings report, missing expectations of -$0.38. Following the earnings report the stock price went down -7.029%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in ARMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$17.50 (52.17% Upside)
$17.50 (52.17% Upside)
Blogger Sentiment
Bearish
ARMP Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 3.9%
Last 30 Days ▼ 3.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
203.60%
12-Months-Change
Fundamentals
Return on Equity
162.59%
Trailing 12-Months
Asset Growth
-20.00%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology enterprise with a global focus on creating specialized bacteriophage therapeutics. Its primary objective is to tackle infections that have developed resistance to standard antibiotics. The company's innovative treatments are developed utilizing its exclusive bacteriophage-based technology platform. Within its product pipeline are several significant candidates: AP-SA02, designed for the treatment of Staphylococcus aureus bacteremia; AP-PA02, targeting Pseudomonas aeruginosa; and AP-PA03, intended to address pneumonia. Additionally, Armata has forged a collaborative agreement with Merck & Co. to further the development of synthetic bacteriophage candidates aimed at specific, yet unrevealed, infectious disease agents. The company's main offices are located in Marina del Rey, California.
ARMP Stock 12 Month Forecast
Average Price Target
$17.50
▲(52.17% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
1.36% Mutual Funds
7.13% Other Institutional Investors
88.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---